Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma

Cancer Cell. 2021 Nov 8;39(11):1442-1444. doi: 10.1016/j.ccell.2021.09.015. Epub 2021 Oct 19.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2019-nCoV Vaccine mRNA-1273
  • Antibodies, Viral / blood
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / immunology
  • B-Lymphocytes / virology
  • BNT162 Vaccine
  • COVID-19 / diagnosis
  • COVID-19 / immunology
  • COVID-19 / prevention & control*
  • COVID-19 / virology
  • COVID-19 Vaccines / administration & dosage*
  • Case-Control Studies
  • Cytokines / blood
  • Host-Pathogen Interactions
  • Humans
  • Immunity, Cellular / drug effects*
  • Immunogenicity, Vaccine*
  • Immunoglobulin G / blood
  • Lymphocyte Activation / drug effects
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / immunology*
  • SARS-CoV-2 / drug effects*
  • SARS-CoV-2 / immunology
  • SARS-CoV-2 / pathogenicity
  • Spike Glycoprotein, Coronavirus / immunology*
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology
  • T-Lymphocytes / virology
  • Treatment Outcome
  • Vaccination

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines
  • Cytokines
  • Immunoglobulin G
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • 2019-nCoV Vaccine mRNA-1273
  • BNT162 Vaccine